nach oben

Drugs

Erschienen in:

01.05.2003 | Leading Article

New Directions in the Diagnosis and Treatment of Chronic Lymphocytic Leukaemia

verfasst von: Dr Folke Schriever, Dieter Huhn

Erschienen in: Drugs | Ausgabe 10/2003

Einloggen, um Zugang zu erhalten

Abstract

Chronic lymphocytic leukaemia (CLL) is the most common leukaemia of adults in Western countries. It is a systemic haematological malignancy that originates from B cells (B-CLL) in 95% of patients, while only a minority are derived through malignant transformation of T cells (T-CLL). Although B-CLL is classified as a non-Hodgkin’s lymphoma, several issues make this leukaemia a unique entity among malignant lymphoma. Inhibition of the programmed cell death (apoptosis) and upregulation of the anti-apoptotic protein Bcl-2 are key elements of the pathophysiology of B-CLL cells and define clinical prognosis. Furthermore, B-CLL cells are arrested in G0/G1 phase of the cell cycle. Dysfunctional apoptosis and cell cycle are the main reasons for the clinical enigma, that CLL can not yet be cured with conventional chemotherapy. However, the molecular pathways that are responsible for this characteristic feature of the B-CLL cells still need further definition.

Recently, considerable progress has been made in defining the molecular basis for the pathogenesis of CLL and in finding new therapeutic options. Recent studies indicate that B-CLL cells may be delineated from two main groups of normal B cells, i.e. pre- and postgerminal B cells, and can be distinguished through lack of or existence of mutations of the V heavy chain gene. This differential mutational status of the Ig V gene has significant impact on patient survival. Modern cytogenetic methods such as fluorescence in situ hybridisation (FISH) have opened a new era in the molecular analysis of CLL cells. Determining the chromosomal aberration of the leukaemic cells has become a standard scientific programme for each clinical trial. The cytogenetic profile may soon help to define a clinical risk profile and guide the various treatment strategies.

Further progress has been made in the therapy of CLL. Purine analogues such as fludarabine were able to induce significant improvement in remission rates; however, they did not lead to improved survival. Chimera of murine or rat monoclonal antibodies and human antibodies were designed to treat CLL. Antibodies such as rituximab and alemtuzumab (Campath-1H), directed against CD20 and CD52, respectively, appear as attractive alternatives to conventional chemotherapy because of their lack of significant myelotoxicity. Studies using myeloablative chemotherapy followed by autologous or allogeneic stem cell transplantation were initiated with the hope of finding a cure for CLL. In contrast to autologous stem cell transplantation, allogeneic transplants appear to display a plateau of relapse rates.

In conclusion, for many years CLL was considered as a chronic haematological malignancy that required only few diagnostic tools and for whom no hope of cure could be offered. The current review focuses on recent improvements in diagnosis and treatment of CLL that have opened a new era in the management of patients with this systemic malignancy.

Döhner H, Stilgenbauer S, Benner A, et al. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis [abstract]. Ann Hematol 1996; 73 Suppl. II: A85

Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87(12): 4990–7PubMed

Binet J, Catovsky D, Dighiero G, et al. Chronic lymphocytic leukemia: recommendations for diagnosis, staging and response criteria — International Workshop on CLL. Ann Intern Med 1989; 110: 236

Matutes E, Owusu-Ankomah K, Morilla R, et al. The immuno-logical profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994; 8(10): 1640–5PubMed

Au WY, Gascoyne RD, Viswanathu DS, et al. Cytogenetic analysis in mantle cell lymphoma: a review of 214 cases. Leuk Lymphoma 2002; 43(4): 783–91PubMedCrossRef

Serke S, Schwaner I, Yordanova M, et al. Monoclonal antibody FMC7 detects a conformational epitope on the CD20 molecule: evidence from phenotyping after rituxan therapy and transfectant cell analyses. Cytometry 2001; 46(2): 98–104PubMedCrossRef

Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia [see comments]. Blood 1999; 94(6): 1840–7PubMed

Thunberg U, Johnston A, Roos G, et al. CD38 expression is a poor predictor for VH gene mutational status and prognosis in chronic lymphocytic leukemia. Blood 2001; 97(6): 1892–4PubMedCrossRef

Ibrahim S, Keating M, Do KA, et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 2001; 98(1): 181–6PubMedCrossRef

10.

German CLL Study Group [online]. Available from URL: http://www.dcllsg.de [Accessed 2003 Mar 24]

11.

Ward JH. Autoimmunity in chronic lymphocytic leukemia. Curr Treat Options Oncol 2001; 2(3): 253–7PubMedCrossRef

12.

Hallek M, Wanders L, Ostwald M, et al. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk Lymphoma 1996; 22(5-6): 439–47PubMedCrossRef

13.

Fais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 1998; 102(8): 1515–25PubMedCrossRef

14.

Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia [see comments]. Blood 1999; 94(6): 1848–54PubMed

15.

Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343(26): 1910–6PubMedCrossRef

16.

Stilgenbauer S, von Neuhoff N, Bullinger L, et al. Deletion of 11q23 identifies B-CLL patients at high risk for molecular disease persistence after high dose therapy and autografting [abstract]. Blood 2000; 96 Suppl. 1: 715a

17.

el Rouby S, Thomas A, Costin D, et al. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 1993; 82(11): 3452–9PubMed

18.

Döhner H, Fischer K, Bentz M, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995; 85(6): 1580–9PubMed

19.

Robertson LE, Plunkett W, McConnell K, et al. Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia 1996; 10(3): 456–9PubMed

20.

Pepper C, Hoy T, Bentley DP. Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. Br J Cancer 1997; 76(7): 935–8PubMedCrossRef

21.

Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46(2): 219–34PubMed

22.

French Cooperative Group on Chronic Lymphocytic Leukemia. Natural history of stage A chronic lymphocytic leukaemia untreated patients. French Cooperative Group on Chronic Lymphocytic Leukaemia. Br J Haematol 1990; 76(1): 45–57CrossRef

23.

French Cooperative Group on Chronic Lymphocytic Leukemia. Effects of chlorambucil and therapeutic decision in initial forms of chronic lymphocytic leukemia (stage A): results of a randomized clinical trial on 612 patients. The French Cooperative Group on Chronic Lymphocytic Leukemia. Blood 1990; 75(7): 1414–21

24.

Brugiatelli M, Jaksic B, Planinc-Peraica A, et al. Treatment of chronic lymphocytic leukemia in early and stable phase of the disease: long-term results of a randomized trial. Eur J Haematol 1995; 55(3): 158–63PubMedCrossRef

25.

Dighiero G. Chronic lymphocytic leukemia treatment. Hematol Cell Ther 1997; 39 Suppl. 1: S31–40PubMedCrossRef

26.

Hisada M, Biggar RJ, Greene MH, et al. Solid tumors after chronic lymphocytic leukemia. Blood 2001; 98(6): 1979–81PubMedCrossRef

27.

Dighiero G, Maloum K, Desablens B, et al. Chlorambucil in indolent chronic lymphocytic leukemia. N Engl J Med 1998; 338(21): 1506–14PubMedCrossRef

28.

CTC G. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists’ Collaborative Group. J Natl Cancer Inst 1999; 91(10): 861–8

29.

Rai K, Peterson B, Appelbaum F, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1750PubMedCrossRef

30.

Knospe WH, Loeb Jr V, Huguley Jr CM. Proceedings: Biweekly chlorambucil treatment of chronic lymphocytic leukemia. Cancer 1974; 33(2): 555–62PubMedCrossRef

31.

Jaksic B, Brugiatelli M, Krc I, et al. High dose chlorambucil versus Binet’s modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia: results of an international multicenter randomized trial. International Society for Chemo-Immunotherapy, Vienna. Cancer 1997; 79(11): 2107–14PubMedCrossRef

32.

Keating MJ, O’Brien S, Lerner S, et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 1998; 92(4): 1165–71PubMed

33.

Romano MF, Lamberti A, Tassone P, et al. Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells. Blood 1998; 92(3): 990–5PubMed

34.

Consoli U, El-Tounsi I, Sandoval A, et al. Differential induction of apoptosis by fludarabine monophosphate in leukemic B and normal T cells in chronic lymphocytic leukemia. Blood 1998; 91(5): 1742–8PubMed

35.

Kitada S, Andersen J, Akar S, et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood 1998; 91: 3379–89PubMed

36.

Klein A, Miera O, Bauer O, et al. Chemosensitivity of B-cell chronic lymphocytic leukemia cells and correlated expression of proteins regulating apoptosis, cell cycle and DNA-repair. Leukemia 2000; 14: 40–6PubMedCrossRef

37.

Kemena A, O’Brien S, Kantarjian H, et al. Phase II clinical trial of fludarabine in chronic lymphocytic leukemia on a weekly low-dose schedule. Leuk Lymphoma 1993; 10(3): 187–93PubMedCrossRef

38.

Robertson LE, O’Brien S, Kantarjian H, et al. A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia. Leukemia 1995; 9(9): 1444–9PubMed

39.

Bergmann L. Present status of purine analogs in the therapy of chronic lymphocytic leukemias. Leukemia 1997; 11 Suppl. 2: 29–34

40.

Seymour JF, Robertson LE, O’Brien S, et al. Survival of young patients with chronic lymphocytic leukemia failing fludarabine therapy: a basis for the use of myeloablative therapies. Leuk Lymphoma 1995; 18(5-6): 493–6PubMedCrossRef

41.

Söderström K-O, Rinne R, Hopsu-Havu VK, et al. Hodgkin’s disease: a malignancy of follicular dendritic cells? Lancet 1994; 343: 422–3PubMedCrossRef

42.

Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000; 343(24): 1750–7PubMedCrossRef

43.

Leporrier M, Chevret S, Cazin B, et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001; 98(8): 2319–25PubMedCrossRef

44.

Boogaerts MA, Van Hoof A, Catovsky D, et al. Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia. J Clin Oncol 2001; 19(22): 4252–8PubMed

45.

O’Brien SM, Kantarjian HM, Cortes J, et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 2001; 19(5): 1414–20PubMed

46.

Rummel MJ, Kafer G, Pfreundschuh M, et al. Fludarabine and epirubicin in the treatment of chronic lymphocytic leukaemia: a German multicenter phase II study. Ann Oncol 1999; 10(2): 183–8PubMedCrossRef

47.

Morrison VA, Rai KR, Peterson BL, et al. Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011. J Clin Oncol 2001; 19(16): 3611–21PubMed

48.

Manero GG, O’Brien S, Cortes J, et al. Update of results of the combination of fludarabine, cyclophosphamide and rituximab for previously treated patients with CLL. Blood 2001; 98: 633a

49.

Wierda W, O’Brien S, Albitar M, et al. Combined fludarabine, cyclophosphamide and rituximab achieves a high complete remission rate as initial treatment for CLL [abstract]. Blood 2001; 98: 771aCrossRef

50.

Myint H, Copplestone JA, Orchard J, et al. Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Br J Haematol 1995; 91(2): 341–4PubMedCrossRef

51.

Robak T, Blasinka-Morawiec M, Krykowski E, et al. Intermittent 2-hour intravenous infusions of 2-chlorodeoxyadenosine in the treatment of 110 patients with refractory or previously untreated B-cell chronic lymphocytic leukemia. Leuk Lymphoma 1996; 22(5-6): 509–14PubMed

52.

Juliusson G, Christiansen I, Hansen MM, et al. Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia. J Clin Oncol 1996; 14(7): 2160–6PubMed

53.

Juliusson G, Liliemark J. High complete remission rate from 2-chloro-2’-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count. J Clin Oncol 1993; 11(4): 679–89PubMed

54.

Robak T, Blonski JZ, Kasznicki M, et al. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood 2000; 96(8): 2723–9PubMed

55.

Saven A, Lemon RH, Kosty M, et al. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J Clin Oncol 1995; 13(3): 570–4PubMed

56.

Kath R, Blumenstengel K, Fricke HJ, et al. Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. J Cancer Res Clin Oncol 2001; 127(1): 48–54PubMedCrossRef

57.

Schulte K, Aivado M, Neise M, et al. Bendamustine is a safe and effective therapy in heavily pretreated patients with B-CLL chronic lymphocytic leukemia, even with pre-existing autoimmune phenomena [abstract]. Blood 2001; 98(11): 292b

58.

Golay J, Lazzari M, Facchinetti V, et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD 59. Blood 2001; 98(12): 3383–9PubMedCrossRef

59.

Bellosillo B, Villamor N, Lopez-Guillermo A, et al. Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Blood 2001; 98(9): 2771–7PubMedCrossRef

60.

Huhn D, von Schilling C, Wilhelm M, et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 2001; 98(5): 1326–31PubMedCrossRef

61.

Winkler U, Jensen M, Manzke O, et al. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999; 94(7): 2217–24PubMed

62.

Byrd JC, Waselenko JK, Maneatis TJ, et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol 1999; 17(3): 791–5PubMed

63.

Kunzmann V, Ruediger T, Hallek M, et al. Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) treatment. Blood 2001; 98(6): 1991–2PubMedCrossRef

64.

Jensen M, Winkler U, Manzke O, et al. Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lympho-cytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab). Ann Hematol 1998; 77(1–2): 89–91PubMedCrossRef

65.

Foran JM, Rohatiner AZ, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000; 18(2): 317–24PubMed

66.

Hainsworth JD, Burns III HA, Morrissey LH, et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 2000; 95(10): 3052–6PubMed

67.

Byrd J, Murphy T, Howard R, et al. Rituximab using a thrice weekly dosing schedule in B cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001; 19(8): 2153–64PubMed

68.

O’Brien S, Kantarjian H, Thomas D, et al. Rituximab doseescalation in chronic lymphocytic leukemia. J Clin Oncol 2001; 19(8): 2165–70PubMed

69.

Pickartz T, Ringel F, Wedde M, et al. Selection of B-cell chronic lymphocytic leukemia cell variants by therapy with anti-CD20 monoclonal antibody rituximab. Exp Hematol 2001; 29(12): 1410–6PubMedCrossRef

70.

Schulz H, Klein SK, Rehwald U, et al. Phase II study of rituximab in combination with fludarabine in patients with CLL [abstract]. Blood 2001; 98: 364a

71.

Czuczman MS, Fallou A, Mohr A, et al. Phase II study of rituximab plus fludarabine in patients with low-grade lymphoma: final report [abstract]. Blood 2001; 98: 601a

72.

Davis TA, Grillo-Lopez AJ, White CA, et al. Rituximab antiCD20 monoclonal antibody therapy in non-Hodgkin’s lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000; 18(17): 3135–43PubMed

73.

Bannerji R, Kitada S, Flinn JW, et al. Campath-1H antibody induces transmembrane signalling in vitro and in vivo in patients with CLL and promotes tumor clearance in part through caspase mediated apoptosis [abstract]. Blood 2001; 98: 808a

74.

Lundin J, Osterborg A, Brittinger G, et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin’s lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin’s Lymphoma. J Clin Oncol 1998; 16(10): 3257–63

75.

Cao TM, Nguyen D, Dugan K, et al. Incidence of cytome-galovirus viremia during campath-1H therapy for relapsed/ refractory CLL and prolymphocytic leukemia [abstract]. Blood 2001; 98: 366a

76.

Stilgenbauer S, Scherer K, Kröber A, et al. Campath-lH in refractory B-CLL — complete remission despite p53 gene mutation [abstract]. Blood 2001; 98: 771aCrossRef

77.

Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99(10): 3554–61PubMedCrossRef

78.

Byrd JC, Shinn C, Ravi R, et al. Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells. Blood 1999; 94(4): 1401–8PubMed

79.

Varterasian ML, Mohammad RM, Shurafa MS, et al. Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. Clin Cancer Res 2000; 6(3): 825–8PubMed

80.

Ahmad I, Al-Katib AM, Beck FW, et al. Sequential treatment of a resistant chronic lymphocytic leukemia patient with bryostatin 1 followed by 2-chlorodeoxyadenosine: case report. Clin Cancer Res 2000; 6(4): 1328–32PubMed

81.

Byrd JC, Shinn C, Waselenko JK, et al. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p 53. Blood 1998; 92(10): 3804–16PubMed

82.

Kitada S, Zapata JM, Andreeff M, et al. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 2000; 96(2): 393–7PubMed

83.

Pepper C, Thomas A, Hoy T, et al. Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukaemia. Br J Haematol 2001; 114(1): 70–7PubMedCrossRef

84.

Wierda WG, O’Brien S. Immunotherapy of chronic lymphocytic leukemia. Expert Rev Anticancer Ther 2001; 1(1): 73–83PubMedCrossRef

85.

Wierda WG, Cantwell MJ, Woods SJ, et al. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 2000; 96(9): 2917–24PubMed

86.

Flaherty KT, Stevenson JP, O’Dwyer PJ. Antisense therapeutics: lessons from early clinical trials. Curr Opin Oncol 2001; 13(6): 499–505PubMedCrossRef

87.

Jahrsdorfer B, Jox R, Muhlenhoff L, et al. Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN. J Leukoc Biol 2002; 72(1): 83–92PubMed

88.

Pepper C, Hooper K, Thomas A, et al. Bcl-2 antisense oligonucleotides enhance the cytotoxicity of chlorambucil in B-cell chronic lymphocytic leukaemia cells. Leuk Lymphoma 2001; 42(3): 491–8PubMedCrossRef

89.

Provan D, Bartlett-Pandite L, Zwicky C, et al. Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood 1996; 88(6): 2228–35PubMed

90.

Montserrat E, Esteve J, Schmitz N, et al. Autologous stem-cell transplantation (ASCT) for chronic lymphocytic leukemia (CLL): results in 107 patient [abstract]. Blood 1999; 94 Suppl. 1: 397a

91.

Dreger P, Michallet M, Schmitz N. Stem-cell transplantation for chronic lymphocytic leukemia. Ann Oncol 2000; 11 Suppl. 1: 49–53PubMedCrossRef

92.

Esteve J, Villamor N, Colomer D, et al. Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status. Leukemia 2001; 15(3): 445–51PubMedCrossRef

93.

Dreger P, van Biezen A, Brand R, et al. Outcome after autologous stem cell transplantation for CLL: a prognostic factor analysis from the EBMT database [abstract]. Hematol J 2001; 1 Suppl. 1: 219a

94.

Esteve J, Montserrat E. Hematopoietic stem-cell transplantation for B-cell chronic lymphocytic leukemia: current status. Rev Clin Exp Hematol 2000; 4: 167–78CrossRef

95.

van Besien K, Keralavarma B, Devine S, et al. Allogeneic and autologous bone marrow transplantation for chronic lymphocytic leukemia. Leukemia 2001; 15: 1317–25PubMedCrossRef

96.

Rabinowe SN, Soiffer RJ, Gribben JG, et al. Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood 1993; 82(4): 1366–76PubMed

97.

Mattsson J, Uzunel M, Remberger M, et al. Minimal residual disease is common after allogeneic stem cell transplantation in patients with B cell chronic lymphocytic leukemia and may be controlled by graft-versus-host disease. Leukemia 2000; 14(2): 247–54PubMedCrossRef

98.

Khouri IF, Keating M, Korbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16(8): 2817–24PubMed

99.

Schetelig J, Held TK, Bornhäuser M, et al. Nonmyeloablative stem cell transplant in chronic lymphocytic leukemia from related and unrelated donors [abstract]. Blood 2000; 96 Suppl. 1: 200a

100.

Rawstron AC, Kennedy B, Evans PA, et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 2001; 98(1): 29–35PubMedCrossRef

101.

Sanchez ML, Almeida J, Vidriales B, et al. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation. Leukemia 2002; 16(8): 1460–9PubMedCrossRef

102.

Noy A, Verma R, Glenn M, et al. Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment CLL protocol. Blood 2001; 97(7): 1929–36PubMedCrossRef

103.

Pfitzner T, Reiser M, Barth S, et al. Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia. Ann Hematol 2002; 81(5): 258–66PubMedCrossRef

104.

Clavio M, Miglino M, Spriano M, et al. First line Fludarabine treatment of symptomatic chronic lymphoproliferative diseases: clinical results and molecular analysis of minimal residual disease. Eur J Haematol 1998; 61(3): 197–203PubMedCrossRef

105.

Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 2001; 345(4): 241–7PubMedCrossRef

106.

Johnson T, Press O. Therapy of B-cell lymphomas with monoclonal antibodies and radioimmunoconjugates: the Seattle experience. Ann Hematol 2001; 79(4): 175–82CrossRef

107.

Ruf P, Lindhofer H. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 2001; 98(8): 2526–34PubMedCrossRef

108.

Davis T, Maloney D, Czerwinski D, et al. Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin’s lymphoma without eradicating the malignant clone. Blood 1998; 92(4): 1184–90PubMed

Titel: New Directions in the Diagnosis and Treatment of Chronic Lymphocytic Leukaemia
verfasst von: Dr Folke Schriever
Dieter Huhn
Publikationsdatum: 01.05.2003
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 10/2003
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200363100-00003

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

New Directions in the Diagnosis and Treatment of Chronic Lymphocytic Leukaemia

Abstract

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2003

Recombinant Hepatitis B Vaccine (Engerix-B®)

Pranlukast

Pulse Pressure

Invasive Oesophageal Candidiasis

Is There a Role for α-Glucosidase Inhibitors in the Prevention of Type 2 Diabetes Mellitus?